BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/7/2016 11:01:00 AM | Browse: 910 | Download: 1396
Publication Name World Journal of Clinical Oncology
Manuscript ID 22547
Country/Territory France
Received
2015-09-02 11:56
Peer-Review Started
2015-09-08 11:32
To Make the First Decision
2015-10-08 16:40
Return for Revision
2015-10-16 19:54
Revised
2015-10-23 22:39
Second Decision
2015-12-17 18:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-01-04 17:13
Articles in Press
2016-01-04 17:20
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2016-03-28 14:16
Publish the Manuscript Online
2016-04-07 11:01
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Off-label use of targeted therapies in oncology
Manuscript Source Invited Manuscript
All Author List Dominique Levêque
Funding Agency and Grant Number
Corresponding Author Dominique Levêque, PhD, Division of Pharmacy, hôpital Hautepierre, avenue Molière, 67000 Strasbourg, France. dominique.leveque@chru-strasbourg.fr
Key Words Targeted therapy; Monoclonal antibody; Off-label anticancer drug use; Reimbursement; Enzyme inhibitor
Core Tip Off-label use is defined by the prescription of a marketed drug outside the conditions described in the summary of product characteristics. This review is the first one focussing on the off-label use of targeted therapies in oncology. When compared with older agents, off-label use of targeted therapies is probably more rational through tumoral genotyping but is faced with a limited clinical support, reimbursement challenges related to the very high pricing and the cost of genotyping or molecular profiling, when applicable.
Publish Date 2016-04-07 11:01
Citation Levêque D. Off-label use of targeted therapies in oncology. World J Clin Oncol 2016; 7(2): 253-257
URL http://www.wjgnet.com/2218-4333/full/v7/i2/253.htm
DOI http://dx.doi.org/10.5306/wjco.v7.i2.253
Full Article (PDF) WJCO-7-253.pdf
Full Article (Word) WJCO-7-253.doc
Manuscript File 22547-Review.doc
Answering Reviewers 22547-Answering reviewers.pdf
Audio Core Tip 22547-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 22547-Conflict-of-interest statement.pdf
Copyright License Agreement 22547-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 22547-Language certificate.pdf
Peer-review Report 22547-Peer-review(s).pdf
Scientific Misconduct Check 22547-Scientific misconduct check.pdf
Scientific Editor Work List 22547-Scientific editor work list.pdf